Until a few years ago, eosinophilic disorders were largely invisible. Only medical specialists and diagnosed patients knew they existed.
Thanks in part to marketing campaigns by AstraZeneca, GlaxoSmithKline and Sanofi and Regeneron for eosinophilic asthma therapies Fasenra, Nucala and Dupixent, respectively, more people now know about eosinophils and their inflammation connection.
Now, a new indication target is coming—eosinophilic esophagitis (EoE). The rare condition, which may affect up to 175,000 people in the U.S., causes white-blood cell allergic overload and problems for patients when swallowing food.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,